MIRA
INFORM REPORT
|
Report Date : |
08.05.2007 |
IDENTIFICATION DETAILS
|
Name : |
WAFRA PHARMA
LABORATORIES |
|
|
|
|
Registered Office : |
|
|
|
|
|
Country : |
|
|
|
|
|
Date of Incorporation : |
1983 |
|
|
|
|
Legal Form : |
Limited Liability Company |
|
|
|
|
Line of Business : |
Engaged in the
manufacture of syrups, tablets, pharmaceuticals and other medical products. |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Maximum Credit Limit : |
US$ 300,000 |
|
|
|
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
SUMMARY
Company Name : WAFRA PHARMA LABORATORIES
Country of Origin :
Legal Form : Limited Liability Company
Registration Date : 1983
Issued Capital : SD 50,000,000
Paid up Capital : SD 50,000,000
Total Workforce : 250
Line of Business : Manufacture of syrups, tablets, pharmaceuticals
and other medical products
Financial Condition : Undetermined
Payments : Nothing detrimental uncovered
COMPANY NAME
WAFRA PHARMA LABORATORIES
ADDRESS
Registered & Physical Address
Location :
PO Box : 2035
Town :
Country :
Telephone : (249-187) 561617 / 571136 / 562409
Facsimile : (249-187) 562408 / 713421
Email : waframed@sudanmail.net
Premises
Subject operates
from a large suite of offices and a factory that are owned and located in the
Industrial Area of Omdurman.
KEY PRINCIPALS
·
Dr
Ahmed Abdullah Gargar Managing
Director
·
Abdulrazak
Mustafa Director
·
Ali
Mohamed Al Miam Commercial
Manager
·
Dr
Hager Mohamed Finance
Manager
·
Hisham
Dharam Technical
Manager
LEGAL FORM &
OWNERS
Date of Establishment : 1983
Legal Form :
Limited Liability Company
Issued Capital : SD 50,000,000
Paid up Capital : SD 50,000,000
Name of Shareholder
(s)
·
National
Trust for Development of Medical Practices *
* The National Trust for Development of Medical Practices is wholly
owned by the Sudanese government.
LINE OF BUSINESS
Operations: Engaged in the manufacture of syrups,
tablets, pharmaceuticals and other medical products.
Import
Countries:
Brand Names: WAFRA
Subject has a
workforce of approximately 250 employees.
FINANCIAL HIGHLIGHTS
Companies
registered in
BANKERS
·
Omdurman
National Bank
Tel : (249-187) 770400 / 775049
PAYMENT HISTORY
No complaints
regarding subject’s payments have been reported.
GENERAL COMMENTS
Wafra Pharma
Laboratories is well established in the Sudanese market, with operations dating
back to the year 1983. The Company specialises in the manufacture of syrups,
tablets, pharmaceuticals and other medical products under the brand name of
“Wafra”.
The Company is run in a professional manner and is owned by The National
Trust for Development of Medical Practices, which in turn is wholly owned by
the Sudanese government.
During the course
of this investigation nothing detrimental was uncovered regarding subject’s
operating history or the manner in which payments are fulfilled. As such the
company is considered to be a fair trade risk.
Maximum suggested
credit figure: US$ 300,000
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average/normal. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)